Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipilimumab and Nivolumab with Chemoradiation in Stage III NSCLC
NCT03663166Phase 2Terminated
- Sponsor
- Moffitt Cancer Center
- Start
- Nov 2018
- Primary completion
- Oct 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ipilimumab, nivolumab in non-small cell lung cancer (NSCLC), sponsored by Moffitt Cancer Center. Started Nov 2018; status: terminated.
02
Drugs
ipilimumabnivolumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03663166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03663166.